About Sana Biotechnology
Sana Biotechnology is a company based in Seattle (United States) founded in 2018 by Michael Mee, Jacob Rubens, and Geoffrey Von Maltzahn. Sana Biotechnology has raised $821 million across 1 funding round from investors including Flagship Pioneering, Baillie Gifford and CPP Investments. The company has 194 employees as of December 31, 2024. Sana Biotechnology has completed 1 acquisition, including Oscine Therapeutics. Sana Biotechnology offers products and services including Engineered Cell Therapies and Drug Candidates. Sana Biotechnology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Seattle, United States
- Employees 194 as on 31 Dec, 2024
- Founders Michael Mee, Jacob Rubens, Geoffrey Von Maltzahn
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sana Biotechnology, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$266.76 M (USD)5.82as on Dec 31, 2024
-
EBITDA
-$255.98 M (USD)13.21as on Dec 31, 2024
-
Total Equity Funding
$821 M (USD)
in 1 rounds
-
Latest Funding Round
$821 M (USD), Series D
Jun 25, 2020
-
Investors
Flagship Pioneering
& 10 more
-
Employee Count
194
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sana Biotechnology
Sana Biotechnology is a publicly listed company on the NASDAQ with ticker symbol SANA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sana Biotechnology
Sana Biotechnology offers a comprehensive portfolio of products and services, including Engineered Cell Therapies and Drug Candidates.
Develops treatments by modifying cells to repair genes for diseases.
Advances therapies targeting cancer and autoimmune disorders through innovation.
People of Sana Biotechnology
Unlock access to complete
Unlock access to complete
Funding Insights of Sana Biotechnology
Sana Biotechnology has successfully raised a total of $821M through 1 strategic funding round. The most recent funding activity was a Series D round of $821 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sana Biotechnology
Sana Biotechnology has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Baillie Gifford and CPP Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Sana Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sana Biotechnology
Sana Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oscine Therapeutics.
Investment portfolio details for Sana Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Stem cell-based therapeutics are developed for CNS diseases.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Sana Biotechnology
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sana Biotechnology
Detailed financials for Sana Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sana Biotechnology Comparisons
Peer comparison for Sana Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sana Biotechnology
Sana Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Sana Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sana Biotechnology
Complete news archive for Sana Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sana Biotechnology
Sana Biotechnology was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Sana Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Steve Harr is the current CEO of Sana Biotechnology.
Sana Biotechnology is a funded company, having raised a total of $821M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Sana Biotechnology is 194.
Sana Biotechnology was founded in 2018 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where genetically engineered cell therapies are created to address disorders such as Non-Hodgkin lymphoma, multiple myeloma, diabetes, and central nervous system conditions. Drug candidates like SC291, SC255, SC451, and SC379 are advanced through gene therapy and editing techniques to reprogram cells in the body or replace damaged tissues.
Sana Biotechnology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Sana Biotechnology offers Engineered Cell Therapies and Drug Candidates.
Yes, Sana Biotechnology is publicly traded on NASDAQ under the ticker symbol SANA.
Sana Biotechnology has made 1 acquisition, including Oscine Therapeutics.
Sana Biotechnology has 11 investors. Key investors include Flagship Pioneering, Baillie Gifford, CPP Investments, Arch Venture Partners, and F-Prime Capital.
The ticker symbol of Sana Biotechnology is SANA on NASDAQ.